Skip to main content
Caplight Logo









Agrenvec

Agrenvec

Private
MadridHealthcare & Life Scienceshttps://www.agrenvec.es/

Last Round

Grant

Feb 26, 2025

Total Funding Raised

$1.26M

Company Overview

Agrenvec is a biotechnology company that specializes in the plant-based manufacturing of high-quality recombinant human proteins for skincare, diagnostics, research, and biotechnological applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clean Manufacturing, Fashion & Beauty, Sustainable Materials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

recombinant proteinsmolecular farminganimal-free proteinsplant-based expressioncultivated meatgrowth factorscontract manufacturingbiomanufacturingrecombinant reagentslab-grown meatendotoxin-freetransient expressionNicotiana benthamianabiotech reagentsalternative protein

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Agrenvec Comparables

Compare Agrenvec with similar companies based on industry and business-model similarity.

Agrenvec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Leaf Expression Systems
88%
ORF Genetics
88%
Cape Bio Pharms
86%

Agrenvec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 26, 2025
GrantDec 30, 2022
Series AApr 27, 2010

Agrenvec Investors

Notable investors and investment history

Agrenvec Filings

Explore SEC and related filing metadata, where available.

Agrenvec filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Agrenvec's valuation, stock price, and market status.

Is Agrenvec a public or private company?

Agrenvec is a private company.

What is the current stock price of Agrenvec?

Agrenvec is a private company with no public stock price. No recent secondary market data is available.

How much is Agrenvec worth (valuation)?

Valuation information for Agrenvec is not publicly available.

Can I buy Agrenvec stock?

Agrenvec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Agrenvec's last funding round?

Agrenvec's most recent funding round was Grant on February 26, 2025.

Who are the main investors in Agrenvec?

Key investors in Agrenvec include AXIS Participaciones Empresariales, European Union NextGenerationEU, Caixa Capital Risc, Center for Technological Development and Innovation.

Will Agrenvec IPO soon?

No public IPO plans have been announced for Agrenvec.

How can I track Agrenvec secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Agrenvec's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMadrid
Employee Range15
Year Founded2002
Last FundingFeb 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?